Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Glaucoma: Overview01:25

Glaucoma: Overview

745
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
745
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

557
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
557
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

669
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
669

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pain as an Exploratory Marker of Rehabilitation Engagement After ACL Reconstruction: Combined Ligament Injuries and Digital Disengagement in a Sensor-Based Monitoring Cohort.

Journal of clinical medicine·2026
Same author

TRPC6-Mediated Ca<sup>2+</sup> Influx Activates MAPK and NFκB Signaling and Elicits Pro-Inflammatory and Catabolic Responses in Human Intervertebral Disc Cells.

Cells·2026
Same author

Angiopoietin-2 and vascular endothelial growth factor α inhibition by faricimab reduces pericyte-to-myofibroblast transition and the myofibroblast phenotype in vitro.

Experimental eye research·2026
Same author

Real-Time Perfusion Assessment with Hyperspectral Imaging After Revascularization in Peripheral Artery Disease.

Journal of clinical medicine·2026
Same author

Outcomes of the 63-μm Gelatin Microstent Versus 45-μm Gelatin Microstent: An International Multicenter Study.

Ophthalmology. Glaucoma·2026
Same author

Cysteinyl leukotriene receptor 1 regulates cellular glucose levels in human retinal cells.

Molecular vision·2025

Related Experiment Video

Updated: Sep 10, 2025

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents
10:10

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents

Published on: February 15, 2022

1.5K

Two Machine Learning Models to Economize Glaucoma Screening Programs: An Approach Based on Neural Nets.

Wolfgang Hitzl1,2, Markus Lenzhofer1,2, Melchior Hohensinn1,2

  • 1Department of Ophthalmology and Optometry, Paracelsus Medical University, University Hospital Salzburg, Muellner Hauptstrasse 48, 5020 Salzburg, Austria.

Journal of Personalized Medicine
|August 27, 2025
PubMed
Summary

This study developed neural network models to identify patients who can safely skip glaucoma screening for up to 10 years. The models accurately predicted 100% of cases, excluding 43% of individuals from routine screening.

Keywords:
glaucomamachine learningneural networkpredictionscreening

More Related Videos

Application of Deep Learning-Based Medical Image Segmentation via Orbital Computed Tomography
04:48

Application of Deep Learning-Based Medical Image Segmentation via Orbital Computed Tomography

Published on: November 30, 2022

2.9K
Author Spotlight: Deciphering Electrical Networks Behind Complex Brain Activities and Disorders
05:49

Author Spotlight: Deciphering Electrical Networks Behind Complex Brain Activities and Disorders

Published on: November 1, 2024

960

Related Experiment Videos

Last Updated: Sep 10, 2025

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents
10:10

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents

Published on: February 15, 2022

1.5K
Application of Deep Learning-Based Medical Image Segmentation via Orbital Computed Tomography
04:48

Application of Deep Learning-Based Medical Image Segmentation via Orbital Computed Tomography

Published on: November 30, 2022

2.9K
Author Spotlight: Deciphering Electrical Networks Behind Complex Brain Activities and Disorders
05:49

Author Spotlight: Deciphering Electrical Networks Behind Complex Brain Activities and Disorders

Published on: November 1, 2024

960

Area of Science:

  • Ophthalmology
  • Artificial Intelligence
  • Medical Diagnostics

Background:

  • Glaucoma screening programs often identify many patients who do not require intervention.
  • A significant proportion of individuals remain free of open-angle glaucoma (OAG) or intraocular eye pressure (IOP)-lowering therapy within 10 years.
  • The need exists to identify patients who can be safely excluded from routine screening at the initial examination.

Purpose of the Study:

  • To develop and validate predictive models for identifying individuals who will remain free of OAG and not require IOP-lowering therapy.
  • To assess the feasibility of safely excluding a proportion of patients from glaucoma screening programs based on initial examination data.

Main Methods:

  • Trained and tested two neural network models on data from 6889 subjects undergoing ophthalmological examination.
  • Included a reject option in the models to handle uncertain predictions.
  • Utilized objective optic nerve head and quantitative disc measurements.

Main Results:

  • The first model correctly predicted 100% of cases (253/253) for remaining OAG-free and no IOP-lowering therapy, with predictions rejected in 57% of cases.
  • The second model correctly predicted 100% of cases (271/271) for remaining OAG-free, with predictions rejected in 46.4% of cases.
  • No false-negative or false-positive predictions were made by either model.

Conclusions:

  • Approximately 43% of eyes can be safely excluded from glaucoma screening for up to 10 years.
  • The developed models significantly reduce screening workload for ophthalmologists.
  • Future advancements in predictive models could further enhance efficiency and cost-effectiveness in glaucoma screening.